Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

6.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.4K
Abnormal Proliferation02:23

Abnormal Proliferation

4.7K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

5.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.2K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Leuconostoc pseudomesenteroides YT830: a promising lactic acid bacterial starter culture for synbiotic fermented yak milk products as revealed by metabolic and genomic analyses.

Journal of applied microbiology·2026
Same author

Discovery of Tcf7 regulators with clonally-resolved CRISPR screens identifies Trim28 as a mediator of CD8 T cell differentiation in tumors.

bioRxiv : the preprint server for biology·2026
Same author

Hydrogeochemical Signatures, Genetic Mechanisms, and Sustainable Utilization Potential of Groundwater Resources in a Typical Arid Alluvial-Proluvial Plain of the Closed Qaidam Basin on Tibetan Plateau.

Water environment research : a research publication of the Water Environment Federation·2026
Same author

Visualizing Electrochemical Oxidation and Dissolution of Platinum Surfaces at the Atomic Scale.

Journal of the American Chemical Society·2026
Same author

High-throughput machine learning-aided antibody discovery for cell surface antigens.

Cell systems·2026
Same author

Effects of enhanced recovery after surgery-based nursing on clinical outcomes, psychological well-being, and quality of life in patients undergoing craniotomy for intracranial tumors.

Frontiers in neurology·2026

Related Experiment Video

Updated: Oct 11, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers.

Takahiro Ito1,2,3,4, Michael J Young1, Ruitong Li1

  • 1Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Nature Genetics
|December 3, 2021
PubMed
Summary

Researchers uncovered new cancer vulnerabilities by targeting pairs of genes. Dual inactivation of DUSP4 and DUSP6 specifically harms NRAS and BRAF mutant cells, offering novel therapeutic strategies.

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.3K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.9K

Related Experiment Videos

Last Updated: Oct 11, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.3K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.9K

Area of Science:

  • Genomics
  • Cancer Biology
  • Drug Discovery

Background:

  • Single-gene studies have limitations in identifying cancer vulnerabilities.
  • Functional redundancy between genes can mask therapeutic targets.
  • Understanding digenic dependencies is crucial for novel cancer treatments.

Purpose of the Study:

  • To identify digenic dependencies masked by gene redundancy.
  • To explore the impact of dual gene inactivation on cell viability.
  • To uncover new therapeutic targets in cancer.

Main Methods:

  • Developed a CRISPR paralog targeting library.
  • Investigated viability effects of disrupting 3,284 genes, 5,065 paralog pairs, and 815 paralog families.
  • Utilized multigene perturbation technology.

Main Results:

  • Identified dual inactivation of DUSP4 and DUSP6 selectively impairs growth in NRAS and BRAF mutant cells.
  • Observed hyperactivation of MAPK signaling upon DUSP4/DUSP6 inactivation.
  • Found that cells resistant to MAPK inhibitors are cross-sensitized to DUSP4/DUSP6 perturbations.

Conclusions:

  • Multigene perturbation reveals previously unrecognized digenic vulnerabilities.
  • DUSP4 and DUSP6 inactivation represents a potential therapeutic strategy for specific cancer types.
  • This approach can overcome resistance mechanisms in MAPK-targeted therapies.